Stryker (SYK) Stock Forecast & Price Target

Q: What analysts cover Stryker?

Stryker has been rated by research analysts at Argus , BMO Capital Markets , BTIG Research , Citigroup , Citizens Jmp , Evercore , JPMorgan Chase & Co. , Piper Sandler , Raymond James Financial , Royal Bank Of Canada , Truist Financial , UBS Group , Weiss Ratings , and Wolfe Research in the past 90 days.

$302.92 -0.21 (-0.07%)

As of 09/4/2026 03:58 PM Eastern

Compare

Stryker - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
6

Buy
18

Based on 24 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 6 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for SYK.

Consensus Price Target

$386.28
27.52% Upside

According to the 24 analysts' twelve-month price targets for Stryker, the average price target is $386.28. The highest price target for SYK is $465.00, while the lowest price target for SYK is $315.00. The average price target represents a forecasted upside of 27.52% from the current price of $302.92.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYK Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$386.28	$386.28	$395.33	$430.10
Forecasted Upside	27.52% Upside	14.00% Upside	28.15% Upside	9.41% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Healthcare Companies	Broader Market
Consensus Rating Score	2.79	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	27.52% Upside	928.67% Upside	14.03% Upside
News Sentiment Rating	Positive News See Recent SYK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/13/2026	Citigroup 4 of 5 stars	Joanne Wuensch 2 of 5 stars	Reiterated Rating	Buy
8/13/2026	Wolfe Research 4 of 5 stars	Mike Polark Not Rated	Downgrade	Outperform ➝ Peer Perform
8/3/2026	Citizens Jmp 4 of 5 stars	David Turkaly 3 of 5 stars	Lower Target	Market Outperform	$440.00 ➝ $400.00	+19.13%
7/31/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
7/31/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kendall Au Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$435.00 ➝ $420.00	+30.93%
7/31/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$370.00	+15.35%
7/31/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$420.00 ➝ $390.00	+11.95%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$400.00 ➝ $350.00	+7.71%
7/31/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$330.00 ➝ $340.00	+5.29%
7/31/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$371.00 ➝ $358.00	+2.76%
SpaceX pays a 10X launch penalty (Ad) SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices. Click here to reveal the ticker before Wall Street catches on
7/28/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$400.00	+18.58%
7/9/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$370.00	+12.96%
7/8/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Market Perform ➝ Outperform	$369.00	+12.79%
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$350.00	+8.72%
6/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$410.00 ➝ $407.00	+35.30%
5/4/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$469.00 ➝ $394.00	+33.36%
5/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$361.00	+22.19%
5/1/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$410.00	+35.16%
5/1/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$385.00	+27.40%
5/1/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$315.00	+1.65%
5/1/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kyle Rose Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$435.00 ➝ $400.00	+35.39%
5/1/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$456.00 ➝ $418.00	+35.99%
5/1/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$454.00 ➝ $418.00	+32.85%
3/5/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
3/4/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$465.00	+21.57%
1/26/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$387.00	+8.35%
9/18/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$420.00	+11.54%
5/2/2025	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Wittes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$405.00 ➝ $456.00	+20.75%
1/29/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$400.00 ➝ $440.00	+11.41%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:17 AM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 4, 2026. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

Stryker Co. recently secured FDA De Novo authorization for SportSuite Vision, the first surgical application for intraoperative use with Apple Vision Pro, which brings spatial computing into the operating room and strengthens its digital surgery portfolio.
The company signed a definitive agreement to acquire ZuriMED, adding the commercialized FiberLocker System to its shoulder portfolio to reinforce rotator-cuff repairs, which enhances its orthopedic product offerings.
Stryker Co. reported strong Q2 2026 results with earnings per share of $3.69, beating the consensus estimate of $3.49, and revenue of $6.59 billion, which was up 9.4% year-over-year, demonstrating solid fundamental performance.
The stock currently trades at $302.92, which is below the consensus price target of $386.28, suggesting potential upside for investors as the company maintains a Moderate Buy rating from analysts.
Stryker Co. offers a dividend yield of 1.13% with a payout ratio of 36.48%, providing a steady income stream while maintaining a conservative approach to distributing earnings to shareholders.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

Several major financial institutions have recently lowered their price targets for Stryker Co., including JPMorgan Chase & Co. cutting its target from $400.00 to $350.00 and Piper Sandler reducing its target from $420.00 to $390.00, indicating a more cautious outlook on valuation.
Corporate insiders have sold a total of 351,267 shares valued at approximately $118.2 million over the last ninety days, including significant sales by Director Ronda E Stryker, which may signal a lack of confidence in the current stock price.
The stock has underperformed the broader market over the past year, with the 52-week high at $396.37 and the current price of $302.92 representing a significant decline from peak levels, reflecting broader market pressures on the healthcare sector.
Stryker Co. has a price-to-earnings ratio of 31.39, which is relatively high compared to some peers, and the company's debt-to-equity ratio of 0.59 indicates a moderate level of leverage that could be a concern in a rising interest rate environment.
Short interest in Stryker Co. has increased in recent months, with shares shorted rising to 6.94 million as of August 2026, suggesting that some investors are betting against the stock's future performance.

SYK Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $386.28, with a high forecast of $465.00 and a low forecast of $315.00.

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last twelve months. There are currently 6 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SYK shares.

According to analysts, Stryker's stock has a predicted upside of 27.52% based on their 12-month stock forecasts.

Over the previous 90 days, Stryker's stock had 1 upgrade and 1 downgrade by analysts.

Stryker has been rated by research analysts at Argus, BMO Capital Markets, BTIG Research, Citigroup, Citizens Jmp, Evercore, JPMorgan Chase & Co., Piper Sandler, Raymond James Financial, Royal Bank Of Canada, Truist Financial, UBS Group, Weiss Ratings, and Wolfe Research in the past 90 days.

Analysts like Stryker more than other "healthcare" companies. The consensus rating for Stryker is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Stryker Recommendations

MarketBeat monitors more than a dozen sources for Stryker analyst ratings, with the most recent rating issued on 8/13/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target